Life Sciences Cell Therapy Manufacturing Solutions sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Cell Therapy Manufacturing Solutions
1.1 - About Life Sciences Cell Therapy Manufacturing Solutions sector
Companies in the Life Sciences Cell Therapy Manufacturing Solutions category design, engineer, and produce cell-based therapeutics, spanning autologous and allogeneic modalities. They provide end-to-end capabilities from process development and scale-up to GMP manufacturing, quality control, and logistics. These vendors help sponsors accelerate clinical timelines, de-risk commercialization, and meet global regulatory standards—key attributes analysts seek when evaluating strategic buyers in cell therapy.
Offerings typically include cell engineering platforms with CRISPR or transposon editing, viral and non-viral vector design, closed-system bioreactors and automated cell expansion, GMP-compliant processing suites, in-process analytics and release testing, and digital MES/LIMS for batch records. Many provide cryopreservation and validated cold chain logistics, vein-to-vein orchestration, and apheresis network coordination, as well as regulatory documentation support for IND/CTA filings and technology transfer into commercial-scale production.
Primary customers include clinical-stage biopharma sponsors, large pharmaceutical cell therapy programs, and academic medical centers running investigator-initiated trials. These companies enable faster IND/CTA submissions, higher batch success rates, reduced cost of goods, and scalable autologous or allogeneic manufacturing. Outcomes often include shorter vein-to-vein timelines, improved comparability across sites, and stronger compliance, supporting progression from early trials through licensure and global commercialization.
2. Buyers in the Life Sciences Cell Therapy Manufacturing Solutions sector
2.1 Top strategic acquirers of Life Sciences Cell Therapy Manufacturing Solutions companies
Lyell
HQ: United States
Website
- Description: Provider of cell-based immunotherapies for cancer, leveraging proprietary T-cell reprogramming technologies to enhance T-cell functionality and durability, and advancing candidates such as CAR-T therapy LYL797 and TIL therapy LYL845 through collaborations, licensing and future commercialization.
- Key Products:
- Exhaustion Resistance (ER): Platform that engineers T cells to resist functional exhaustion, sustaining anti-tumor activity and improving durability of cell therapies
- Stemness Technology: Method that maintains T cells in a less differentiated, stem-like state, boosting their proliferation and persistence for stronger, longer cancer responses
- LYL797 CAR-T Therapy: ROR1-targeted CAR-T candidate for multiple solid tumors, integrating ER and Stemness enhancements to increase tumor killing potency and persistence
- LYL845 TIL Therapy: Enhanced tumor-infiltrating lymphocyte treatment that reprograms patient-derived T cells to elevate functionality, durability and anti-cancer efficacy in solid tumors.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Life Sciences Cell Therapy Manufacturing Solutions sector
M&A buyer group 1: Biopharma Outsourcing
95 companies
View group →
Description: Companies in Healthcare Biopharma Outsourcing Services provide contract development, clinical operations, and GMP manufacturing across the drug lifecycle. They build compliant manufacturing networks for biologics, cell and gene therapies, and vaccines; deliver aseptic fill‑finish and dosage‑form development; and run preclinical and clinical programs. Strategic buyers in this category enable sponsors to scale capacity, accelerate approvals, and improve supply resilience through integrated, outsourced capabilities.
Catalent
- Type: N/A
- Employees: ●●●●●
- Description: Provider of advanced drug delivery technologies and development solutions for pharmaceuticals, biologics and consumer health products, offering pre-formulation, formulation, clinical and commercial manufacturing of oral solid dose formats, softgel technologies, and injectable manufacturing including pre-filled syringes and glass-free vials, plus integrated cell-line and formulation development services.
- Key Products:
- Softgel Technologies: Provides formulation, development and manufacturing of soft capsules, utilizing proprietary softgel delivery to enhance bioavailability and create customised dosage forms for health and pharma clients
- Advanced Oral Solid Dose Solutions: Offers comprehensive pre-formulation, formulation, and clinical-to-commercial scale production of traditional and advanced oral solid dose formats, improving drug stability and controlled release profiles
- Injectable Manufacturing Solutions: Delivers sterile filling of drugs and biologics into pre-filled syringes and glass-free vials with integrated formulation development, supporting clinical and commercial supply requirements globally
- Cell-Line & Formulation Development: Supplies integrated cell-line manufacturing and formulation development services that accelerate biologic drug development, enhance production yields and shorten time-to-market for therapeutic clients
🔒
🔒
🔒
View all 95 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Life Sciences Cell Therapy Manufacturing Solutions sector
3.1 - Buyout funds in the Life Sciences Cell Therapy Manufacturing Solutions sector
2.2 - Strategic buyer groups for Life Sciences Cell Therapy Manufacturing Solutions sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Life Sciences Cell Therapy Manufacturing Solutions companies
4.2 - Public trading comparable groups for Life Sciences Cell Therapy Manufacturing Solutions sector
Valuation benchmark group 1: Biopharma Research Tools and CDMOs
10 companies
View group →
Description: This public trading comparables group comprises biopharma service providers and tools vendors that enable discovery, development, and manufacturing of biologics and gene therapies. Business models span outsourced CRO/CDMO services and sale of critical bioprocess equipment, consumables, and analytics. They are comparable for valuation because revenues are tied to pipeline progression, cGMP capacity, and recurring supply contracts, with specialized know-how and regulatory compliance differentiating scale and margins.
Lonza Group
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of comprehensive services and products focusing on the discovery, development, and manufacturing of active pharmaceutical ingredients, biologics, and innovative dosage forms for the pharmaceutical, biotech, and consumer health industries to support the commercialization of various therapies, with a strong commitment to sustainability and zero-incident workplace initiatives.
- Key Products:
- Bioscience Products: Tools and technologies for cell culture, research, and quality control in biomanufacturing
- Capsule Manufacturing: Pharmaceutical services ensuring high-quality capsule products using gelatin, HPMC, or pullulan
- Biologics Manufacturing: Custom development and manufacturing services for biologics from late phase drug discovery to market supply
- API Development: Early phase discovery and manufacturing of active pharmaceutical ingredients for various therapeutic areas
- Healthcare Solutions: Innovative dosage forms and customized solutions for the pharma and consumer health industries.
🔒
🔒
🔒
View all 10 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →